Wolfgang Koenig Selected Research

C-terminal proendothelin-1

1/2022	Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium.
1/2022	Association of C-Terminal Pro-Endothelin-1 with Mortality in the Population-Based KORA F4 Study.
10/2020	Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study.
1/2020	Serum uromodulin is inversely associated with arterial hypertension and the vasoconstrictive prohormone CT-proET-1 in the population-based KORA F4 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfgang Koenig Research Topics

Disease

107	Inflammation (Inflammations) 10/2022 - 07/2002
95	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 07/2002
68	Coronary Disease (Coronary Heart Disease) 01/2021 - 07/2002
64	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2003
60	Myocardial Infarction 10/2022 - 07/2002
43	Atherosclerosis 10/2022 - 04/2002
40	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 07/2002
29	Stroke (Strokes) 12/2021 - 02/2005
24	Hypertension (High Blood Pressure) 01/2022 - 08/2005
22	Insulin Resistance 01/2022 - 10/2006
22	Atherosclerotic Plaque (Atheroma) 12/2021 - 01/2007
21	Acute Coronary Syndrome 01/2022 - 04/2003
18	Obesity 01/2022 - 07/2003
17	Heart Failure 01/2022 - 02/2009
13	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2021 - 11/2003
12	Prediabetic State (Prediabetes) 01/2021 - 07/2011
10	Chronic Renal Insufficiency 01/2022 - 02/2007
10	Dyslipidemias (Dyslipidemia) 12/2020 - 11/2009
9	Thrombosis (Thrombus) 01/2020 - 03/2009
9	Diabetes Mellitus 01/2020 - 01/2003
9	Glucose Intolerance 01/2019 - 12/2005
8	Unstable Angina 10/2018 - 07/2002
8	Neoplasms (Cancer) 10/2017 - 02/2008
7	Chest Pain (Chest Pains) 11/2017 - 03/2009
6	Polyneuropathies (Polyneuropathy) 01/2022 - 01/2015
6	Overweight 11/2021 - 01/2007
5	Abdominal Obesity 01/2022 - 07/2008
5	Kidney Diseases (Kidney Disease) 06/2021 - 11/2009
5	Necrosis 06/2021 - 09/2010
5	Non-alcoholic Fatty Liver Disease 09/2019 - 10/2009
5	Infections 01/2017 - 01/2004
4	Gout 12/2021 - 01/2014
4	Body Weight (Weight, Body) 11/2021 - 11/2011
4	Asthma (Bronchial Asthma) 11/2021 - 01/2009
4	Hyperglycemia 06/2021 - 05/2008
4	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2021 - 08/2016

Drug/Important Bio-Agent (IBA)

96	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2005
80	C-Reactive ProteinIBA 01/2022 - 07/2002
37	LipidsIBA 01/2021 - 07/2002
28	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 02/2006
28	Interleukin-6 (Interleukin 6)IBA 01/2022 - 04/2004
28	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 11/2002
27	LDL CholesterolIBA 01/2021 - 12/2005
25	HDL CholesterolIBA 01/2022 - 01/2004
24	Fibrinogen (Factor I)FDA Link 01/2019 - 02/2003
23	AdiponectinIBA 01/2022 - 08/2005
22	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 01/2020 - 10/2004
18	CholesterolIBA 10/2022 - 10/2005
16	CytokinesIBA 10/2022 - 04/2002
16	TroponinIBA 01/2022 - 03/2010
15	Cystatin CIBA 01/2022 - 02/2005
15	Proteins (Proteins, Gene)FDA Link 06/2021 - 08/2003
15	oxidized low density lipoproteinIBA 01/2021 - 08/2005
14	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 12/2006
14	Insulin (Novolin)FDA Link 01/2022 - 02/2006
13	LeptinIBA 01/2022 - 02/2008
13	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 04/2010
13	Troponin T (Troponin T1)IBA 01/2021 - 03/2010
12	darapladibIBA 12/2021 - 05/2014
12	Lipoproteins (Lipoprotein)IBA 02/2021 - 05/2003
11	AdipokinesIBA 01/2022 - 08/2004
11	InterleukinsIBA 06/2021 - 10/2005
11	Triglycerides (Triacylglycerol)IBA 10/2020 - 06/2013
10	CreatinineIBA 01/2022 - 12/2006
10	ChemokinesIBA 11/2018 - 12/2005
9	Uric Acid (Urate)IBA 12/2021 - 12/2005
9	ApolipoproteinsIBA 04/2019 - 10/2003
9	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2013 - 11/2002
7	omega-Chloroacetophenone (Mace)IBA 12/2021 - 07/2008
7	Natriuretic PeptidesIBA 11/2021 - 12/2006
7	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020 - 11/2008
7	Vitamin D FDA LinkGeneric 01/2019 - 10/2011
7	Lipoprotein(a)IBA 08/2017 - 10/2003
7	Rosuvastatin Calcium (Crestor)FDA Link 05/2012 - 11/2008
7	Chemokine CCL5IBA 01/2011 - 12/2005
6	UromodulinIBA 01/2022 - 03/2019
6	AlbuminsIBA 12/2021 - 12/2010
6	Growth Differentiation Factor 15IBA 01/2021 - 01/2016
6	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2021 - 01/2006
6	Troponin IIBA 01/2021 - 08/2016
6	Interleukin-18 (Interleukin 18)IBA 01/2018 - 10/2005
6	HDL LipoproteinsIBA 01/2018 - 09/2006
6	EnzymesIBA 05/2014 - 01/2007
6	Secretory Phospholipases A2IBA 01/2014 - 02/2009
5	canakinumab FDA Link 10/2022 - 01/2017
5	25-hydroxyvitamin DIBA 01/2022 - 10/2011
5	Peroxidase (Myeloperoxidase)IBA 01/2022 - 06/2012
5	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2022 - 05/2005
5	Peptides (Polypeptides)IBA 01/2022 - 08/2011
5	hydroxide ionIBA 01/2022 - 01/2013
5	PPAR alphaIBA 01/2019 - 04/2002
5	Phospholipases (Phospholipase)IBA 11/2013 - 02/2009
4	Monoclonal AntibodiesIBA 10/2022 - 01/2017
4	InflammasomesIBA 10/2022 - 01/2018
4	ProinsulinIBA 01/2022 - 02/2013
4	C-terminal proendothelin-1IBA 01/2022 - 01/2020
4	ReninIBA 01/2022 - 01/2016
4	AdrenomedullinIBA 01/2021 - 12/2012

Therapy/Procedure

45	Therapeutics 10/2022 - 07/2002
6	Secondary Prevention 01/2019 - 11/2002